This study was conducted to assess the farm prevalence of extended-spectrum β-lactamase (ESBL)-/AmpC-producing E. coli on dairy farms 2 years following a first study conducted in 2011 and to assess the animal prevalence for calves, dairy cows, and young stock. Fecal samples from 196 Dutch dairy herds were screened for E. coli with non-wild type susceptibility for cefotaxime and isolates were confirmed as ESBL/AmpC-producing by the combination disc diffusion test using cefotaxime and ceftazidime with and without clavulanic acid and cefoxitin. Identification of ESBL/AmpC genes was performed by microarray, PCR and sequence analysis. All data were combined and analyzed using Stata 14 at 5% level of significance. Fecal samples collected from 58% of the dairy farms contained ESBL/AmpC-producing E. coli. The between-farm prevalence based on samples collected from the slatted floors (18%) was statistically significantly lower than in 2011 (33%). The animal prevalence among calves was 33%, and only 1 and 2% among dairy cows and young stock, respectively. Plasmid-mediated resistance was predominantly caused by AmpC, encoded by the ACT gene. The predominant ESBL gene type was CTX-M-1. The farm prevalence of ESBL/AmpC-producing E. coli in dairy farms, based on pooled fecal samples of the slatted floor, was significantly reduced in 2013 compared with 2011. However, the farm prevalence based on the fecal samples from cows, young stock and calves is relatively high. Furthermore, the prevalence of ESBL/AmpC-producing E. coli for young calves is high, whereas the prevalence for cows and young stock is low. Moreover, most fecal samples contained a low number of ESBL/AmpC-producing E. coli per gram feces.